|
Characteristics
|
All (n = 54)
|
pCR (n = 10)
|
Non-pCR (n = 36)
|
P
|
|---|
| |
n (%)
|
n (%)
|
n (%)
| |
|---|
|
Age
| | | |
0.67
|
|
Mean(range)
|
63 (48,75)
|
63 (55,70)
|
62 (48,75)
| |
|
≤ 60
|
15 (27.8)
|
2 (20.0)
|
12 (33.3)
| |
|
> 60
|
39 (72.2)
|
8 (80.0)
|
24 (66.7)
| |
|
Sex
| | | |
0.50
|
|
Male
|
49 (90.7)
|
10 (100.0)
|
31 (86.1)
| |
|
Female
|
5 (9.3)
|
0 (0.0)
|
5 (13.9)
| |
|
Tumor location
| | | |
0.28
|
|
Proximal
|
8 (14.8)
|
2 (20.0)
|
5 (13.8)
| |
|
Middle
|
16 (29.6)
|
1 (10.0)
|
13 (36.2)
| |
|
Distal
|
30 (55.5)
|
7 (70.0)
|
18 (50.0)
| |
|
Length, cm
| | | |
0.47
|
|
Mean (range)
|
6 (3,10)
|
6 (4,9)
|
6 (3,10)
| |
|
≤ 6 cm
|
38 (70.4)
|
6 (60.0)
|
28 (77.8)
| |
|
> 6 cm
|
16 (29.6)
|
4 (40.0)
|
8 (22.2)
| |
|
Clinical T stage
| | | |
0.39
|
|
T1-2
|
2 (3.7)
|
1 (10.0)
|
1 (2.8)
| |
|
T3-4
|
52 (96.3)
|
9 (90.0)
|
35 (97.2)
| |
|
Clinical N stage
| | | |
0.61
|
|
N negative
|
3 (48.1)
|
1 (60.0)
|
2 (50.0)
| |
|
N positive
|
51 (51.9)
|
9 (40.0)
|
34 (50.0)
| |
|
Clinical stage
| | | |
0.91
|
|
II
|
2 (3.7)
|
1 (10.0)
|
1 (2.8)
| |
|
III
|
52 (96.3)
|
9 (90.0)
|
35 (97.2)
| |
|
Chemotherapy
| | | | |
|
Weekly
|
32 (59.3)
|
4 (40.0)
|
21 (58.3)
|
0.50
|
|
3-weekly
|
22 (40.7)
|
6 (60.0)
|
15 (41.7)
| |
